Government Response to ACMD 3 Medicines Reports on Drug Scheduling

Correspondence

Government response to 3 medicines reports

This response agrees with recommendations from the Advisory Council on the Misuse of Drugs (ACMD) in 3 reports about the control and scheduling of 5 medicines.

From: Advisory Council on the Misuse of Drugs Published 23 February 2026 Get emails about this page

Documents

Government response to 3 ACMD reports (accessible)

HTML

---

Government response to 3 ACMD reports

PDF, 259 KB, 3 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

---

Details

The government accepts the ACMD ’s recommendations in relation to the classification and scheduling of the 5 medicines featured in the ACMD ’s reports:

• Somapacitan, lonapegsomatropin and somatrogon: ACMD advice
• Ganaxolone: ACMD advice

• Zuranolone: ACMD advice
  The ACMD recommended that:

• the 3 growth hormones somapacitan, lonapegsomatropin, and somatrogon should be controlled under Class C of the Misuse of Drugs Act 1971 and scheduled under Schedule 4 (Part 2) to the Misuse of Drugs Regulations 2001

• ganaxolone, a neuroactive steroid to treat a rare form of epilepsy, should not be controlled under the Misuse of Drugs Act 1971 nor scheduled under the Misuse of Drugs Regulations 2001 at this time

• zuranolone, an oral, synthetic neuroactive steroid (NAS) with rapid antidepressant effects used to treat post natal depression, should be controlled under Class C of the 1971 Act and scheduled under Schedule 4, (Part I) of the 2001 Regulations

Published 23 February 2026 Get emails about this page Print this page